EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, on 27June announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP’s manufacturing site with no findings nor issuance of Form 483 observations. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) net profit margin is -1.40% and weekly performance is 3.43%. On last trading day company shares ended up $5.43. Analysts mean target price for the company is $6.00. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) distance from 50-day simple moving average (SMA50) is 42.93%.
Intellipharmaceutics International Inc. (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, on 7 July reported second-quarter net loss of $3.1 million or $0.14 per share, wider than $1.8 million, or $0.09 per share in the comparable quarter last year. IntelliPharmaCeutics Intl Inc. (USA) (NASDAQ:IPCI) shares fell -12.72% in last trading session and ended the day on $2.95. IPCI return on assets is -139.80%.IntelliPharmaCeutics Intl Inc. (USA) (NASDAQ:IPCI) quarterly performance is -27.34%.
Prosensa Holding N.V. (NASDAQ:RNA) on 7 July filed a $150 million mixed securities shelf. The company also filed to sell up to 18,908,019 Ordinary Shares on behalf of Selling Shareholders. Prosensa Holding NV (NASDAQ:RNA) shares moved down -7.29% in last trading session and was closed at $9.66, while trading in range of $9.56 – $10.52. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 106.85%.
On 26 June Rosetta Genomics Ltd. (USA)(NASDAQ:ROSG) receives a Notice of Allowance from the USPTO for its patent application entitled “Compositions and Methods for Prognosis and Treatment of Prostate Cancer.” The patent (No. 13/390,995) claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) ended the last trading day at $3.73. Company weekly volatility is calculated as 4.93% and price to cash ratio as 1.59.Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) showed a negative weekly performance of -11.40%.
Cellular Dynamics International Inc. (NASDAQ:ICEL) has already situated itself as an early leader—if not the leader—in large-scale manufacturing of human cells from induced pluripotent stem cells. The company says it has strengthened its market position with three new patents related to making stem cells from human blood samples. Cellular Dynamics International Inc. (NASDAQ:ICEL) weekly performance is -18.13%. On last trading day company shares ended up $12.01. Analysts mean target price for the company is $17.33. Cellular Dynamics International Inc. (NASDAQ:ICEL) distance from 50-day simple moving average (SMA50) is -4.70%.